Increased GST and/or GT tumor expression, generally considered as a bad prognosis marker (associated with drug resistance and disease progression), and could potentially be used as a predictive marker, allowing doctors, after biopsy, to identify which patients will respond best to GST or GT-activated prodrugs
Ashima Nayyar, Icahn School of Medicine at Mount Sinai, United States Updates Copyright 2022 Zhang, Wu, Zhu, Yang, Yang, Vuong, Li, Zhu, Sun and Tao
501,502 Clinical trials demonstrated a clinical remission rate of 18.7% at 8 weeks and 27.6% at 24 weeks in patients treated with ustekinumab, with an adverse event rate of 2.3%
Provider-supervised, customized to you
Jin J, Yuan P, Yu W, Lin J, Xu A, Xu X, et al